Shingles vaccine shows 20% dementia risk reduction in landmark study

Vaccines have spent two centuries doing what we expect of them: stopping infectious disease. The World Health Organization credits vaccination with preventing three to five million deaths annually—from diphtheria and tetanus to measles, influenza, and COVID-19. But a study published this year in Nature suggests the story might be larger than that. Researchers found that people who received the shingles vaccine showed a twenty percent reduction in dementia risk over a seven-year period, a finding that hints at therapeutic possibilities far beyond the traditional scope of immunization.

The challenge in vaccine research has always been finding a fair comparison. You cannot ethically tell one group of people they cannot have a vaccine while giving it to another, simply to measure the difference. But in 2013, Wales changed its vaccination policy in a way that created what researchers call a natural laboratory. The new rule made the shingles vaccine available to anyone born on or after September 2, 1933, while those born before that date were not eligible. The vaccine prevents shingles, a painful reactivation of the chickenpox virus that can emerge decades after the initial infection. Using health records and sophisticated statistical analysis, researchers compared the two groups—similar in age and medical history—and found that the vaccinated cohort developed dementia at lower rates. Women showed greater protection than men.

The mechanism remains unclear. One possibility is direct: the shingles virus itself may contribute to dementia's development, and the vaccine prevents that contribution. Another is broader: vaccination might activate what scientists call "trained immunity," a state in which the immune system becomes generally strengthened and more vigilant. The study did not distinguish between types of dementia—Alzheimer's disease versus stroke-related dementia, for instance—nor could researchers draw firm conclusions about how the protection works from health records alone. What they found was correlation, not causation, and that distinction matters.

Dementia itself is becoming harder to ignore. A January 2025 study revised estimates upward dramatically: the lifetime risk of dementia after age fifty-five is now calculated at forty-two percent, more than double what researchers previously believed. By age eighty-five, the risk reaches twenty percent. The United States alone is projected to see new dementia cases double from roughly five hundred fourteen thousand in 2020 to one million by 2060. The disease is no longer confined to wealthy nations; as life expectancy rises globally, dementia follows.

For decades, Alzheimer's research has centered on a single hypothesis: that a protein called amyloid accumulates in the brain and causes the disease. Billions in research funding have pursued drugs to lower amyloid levels. The results have been modest. The two recently approved amyloid-lowering therapies slow decline only minimally, cost substantially, and carry serious side effects. No approved drug reverses cognitive decline. Meanwhile, emerging evidence from health records suggests that past viral infections increase dementia risk, while routine vaccines—against tetanus, diphtheria, pertussis, pneumonia, and shingles—appear to reduce it.

The shingles vaccine finding opens a door that many researchers have been reluctant to walk through. Science has a tendency to cling to established models, to follow the well-worn path. But the data sometimes pulls in unexpected directions. Before any vaccine can be recommended for dementia prevention, researchers will need to conduct what they call the gold standard: a prospective, randomized, double-blind, placebo-controlled trial that directly compares the shingles vaccine to a placebo and measures dementia outcomes over time. Such studies take years and substantial resources. They are also the only way to move from observation to clinical recommendation. The shingles vaccine study is not the end of this story. It is an opening.